PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer

Immunotherapy combined with chemotherapy has become the standard first-line treatment regimen for gastric cancer. However, a subset of patients still fail to benefit or derive only limited benefit from this approach. This study aims to evaluate the addition of immunomodulatory EZH2 inhibitors or anti-angiogenic agents to the baseline regimen of immunotherapy combined with chemotherapy, in order to further improve patient treatment benefits.

NCT Number	NCT07294664
Lead Sponsor	The First Affiliated Hospital of Zhengzhou University
Conditions	Advanced Gastric Cancer, SHR1701
Enrollment	78 participants
Start Date	2025-06-15
Primary Completion	2027-07-15 (estimated)
Study Completion	2028-07-15 (estimated)
Updated on ClinicalTrials.gov	2026-04-16